Revive Therapeutics Ltd. ("Revive" or the "Company") , a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, rare disorders, and medical ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, will announce new clinical findings for ANKTIVA® ...

FYARRO holds strong market potential, particularly in treating rare and aggressive cancers like PEComa, where treatment options are limited. As the first FDA-approved therapy for advanced PEComa ...

DelveInsight's "FYARRO Market Size, Forecast, and Market Insight Report" highlights the details around FYARRO, an mTOR ...

ImmunityBio announces US FDA submissions of sBLA for NMIBC papillary disease and EAP for Anktiva to treat lymphopenia: Culver City, Calif Thursday, April 17, 2025, 15:00 Hrs [IST] ...

The stock market fell sharply anew on Wednesday, with all major indices ending in the red, as investor sentiment was dampened ...

A supplemental Biologics License Application has been submitted to the FDA for Anktiva plus BCG in papillary NMIBC.

The Abu Dhabi health care company M42 is to make an investment in biotech longevity specialist Juvenescence as a route to moving into drug discovery and development, with the two forming a partnership ...

In terms of financial performance, ImmunityBio reported that its Q1 2025 Anktiva unit sales volume grew by 150% over the unit ...

Port Therapeutics and other early biotech startups face funding challenges as investors prefer clinical-stage companies, with ...

ImmunityBio, Inc.’s IBRX share price has dipped by 6.65%, which has investors questioning if this is right time to buy.

A supplemental biologics license application has been submitted to the FDA for nogapendekin alfa plus Bacillus ...